Alexandria Real Estate Equities, Inc. (ARE)
Alexandria Real Estate Equities (ARE) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Alexandria Real Estate Equities (ARE) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Alexandria Real Estate Equities (ARE) Lags Q3 FFO and Revenue Estimates
Alexandria Real Estate Equities (ARE) came out with quarterly funds from operations (FFO) of $2.22 per share, missing the Zacks Consensus Estimate of $2.31 per share. This compares to FFO of $2.37 per share a year ago.
More Rate Cuts Are Coming: Grab 6% High-Yield S&P 500 Stocks Now
Investors love dividend stocks, especially those with high yields, because they provide a substantial income stream and offer significant total return potential.
Alexandria to Post Q3 Earnings: What to Expect From the Stock?
ARE's Q3 results may show lower revenues and FFO as occupancy pressures weigh on performance.
Alexandria Real Estate Equities Is A Great Prospect Despite Real Challenges
Alexandria Real Estate Equities remains a "Strong Buy" due to its attractive valuation and strategic position in the life sciences REIT sector. ARE is actively recycling its portfolio, selling non-revenue assets and reinvesting proceeds to reduce debt and fund new developments, despite recent revenue and profit declines. The company's megacampus strategy and focus on life sciences position it for long-term growth, even as sector vacancy rates and industry headwinds persist.
The Real Catalyst Behind Alexandria Real Estate
Alexandria Real Estate generated an 11% return in Q3. It may be starting to turn around its performance. With a 6.3% yield, a 57% payout ratio, and solid AFFO, ARE's dividend security stands out among healthcare REITs despite sector headwinds. I analyzed a catalyst that investors sometimes forget about in ARE: the potential of Big Pharma and Big Biotech.
Two Retirement Bargains With Upside Potential
As retirement nears, portfolio focus should shift from growth to downside protection and stable income. For most of us it is crucial to limit drawdown risk, maintain income streams, and preserve inflation-adjusted value. Here ultra-conservative assets may not suit well.
Alexandria Stock Gains 19.3% in 3 Months: Will the Trend Continue?
ARE stock's 19.3% rise in three months is fueled by demand for its Class A/A+ properties, strong occupancy and solid financial footing.
What I Wish I Knew Before Becoming A REIT Investor
I have made many mistakes in my REIT investing career. Some of which have cost me dearly. Learn from me to improve your future investment results.
My Top 3 AI Stocks In Real Estate
Artificial intelligence is set to revolutionize the world we live in. I think that it is a major headwind for most stocks. But it could turn into a huge tailwind for certain real assets.
Alexandria Real Estate For 20%+ Total Return And 6%+ Yield
ARE offers a 6.4% dividend yield at a steep discount, with strong long-term fundamentals and a leading position in life sciences real estate. Recent share price weakness is due to tenant concessions, asset dispositions, and post-pandemic demand normalization, but recovery is expected as concessions expire. Pipeline developments, high occupancy, and potential EU investment should drive FFO growth, supporting a projected 15-20% annual total return over five years.
Alexandria Real Estate Q2: Deep Value Sharks Play With Patience
Alexandria Real Estate is one of those rare deep value investments that's currently in prime buying territory. I forecast a 40% total return from the investment over the next 18 months. There are specific medium-term macro and operational catalysts that are likely to cause the market to re-rate ARE's valuation multiples higher as the six-month mark approaches.
